◀ Back to AKT3

AKT3 — HDAC3

Text-mined interactions from Literome

De Sarno et al., Neuropharmacology 2002 : Two other inhibitors of histone deacetylase , a recently identified target of sodium valproate, also caused gradual increases in the phosphorylation of Akt and GSK3beta
Chen et al., J Biol Chem 2005 : Histone acetylation independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes
Lefebvre et al., Mol Endocrinol 2006 : Through direct phosphorylation of the corepressor silencing mediator for retinoic and thyroid hormone receptors ( SMRT ), Akt stabilized RAR/SMRT interaction, leading to an increased tethering of SMRT to the RARbeta2 promoter, decreased histone acetylation, down-regulation of the RARbeta2 expression, and impaired cellular differentiation in response to retinoid
Furuya et al., Mol Cell Biol 2007 (Thyroid Neoplasms) : Conversely, lowering cellular NCoR by siRNA knockdown in tumor cells led to overactivated p-AKT and increased cell proliferation and motility
Lee et al., Mol Pharmacol 2008 : Finally, activation of Akt and CaM kinase II may eventually lead to the acetylation of histone residues and phosphorylation of histone deacetylase
Furuya et al., Steroids 2009 (Thyroid Neoplasms) : Over-expression of NCoR in thyroid tumor cells of TRbeta ( PV/PV ) mice reduces AKT-mTOR-p70 ( S6K ) signaling ... Conversely, lowering cellular NCoR by siRNA knockdown in tumor cells leads to over activated PI3K-AKT signaling to increase cell proliferation and motility
Zampetaki et al., Circulation 2010 (Atherosclerosis) : Enforced expression of HDAC3 resulted in increased phosphorylation of Akt and upregulation of its kinase activity
Moskowitz et al., Curr Oncol Rep 2012 (Hodgkin Disease) : Additional agents that have demonstrated activity in HL include histone deacetylase inhibitors, such as panobinostat, entinostat, and mocetinostat, PI3-kinase/Akt/Mtor pathway inhibitors , such as everolimus, as well as lenalidomide and bendamustine